Screening and prostate-cancer mortality in a randomized European study.

@article{Schrder2009ScreeningAP,
  title={Screening and prostate-cancer mortality in a randomized European study.},
  author={F. Schr{\"o}der and J. Hugosson and M. Roobol and T. Tammela and S. Ciatto and V. Nelen and M. Kwiatkowski and M. Luj{\'a}n and H. Lilja and M. Zappa and L. Denis and F. Recker and A. Berenguer and L. M{\"a}{\"a}tt{\"a}nen and C. Bangma and G. Aus and A. Villers and X. R{\'e}billard and T. H. van der Kwast and B. G. Blijenberg and S. Moss and H. D. de Koning and A. Auvinen},
  journal={The New England journal of medicine},
  year={2009},
  volume={360 13},
  pages={
          1320-8
        }
}
BACKGROUND The European Randomized Study of Screening for Prostate Cancer was initiated in the early 1990s to evaluate the effect of screening with prostate-specific-antigen (PSA) testing on death rates from prostate cancer. METHODS We identified 182,000 men between the ages of 50 and 74 years through registries in seven European countries for inclusion in our study. The men were randomly assigned to a group that was offered PSA screening at an average of once every 4 years or to a control… Expand
Prostate-cancer mortality at 11 years of follow-up.
Mortality results from a randomized prostate-cancer screening trial.
Prostate Cancer Screening: Outcomes and Risk Prediction
Prostate Cancer Screening
Screening for prostate cancer – The controversy continues, but can it be resolved?
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
Mortality results from a randomized prostate-cancer screening trial.
...
1
2
3
4
5
...